… States Food and Drug Administration (FDA) for olaparib tablets, 100 mg … 150 mg). Olaparib is indicated for treatment of certain types … repair [HRR] genes). Olaparib tablets will be produced at … Zydus Lifesciences Ltd, SEZ. Olaparib tablets had annual sales …

… United States Food and Drug Administration (USFDA) for Olaparib Tablets, 100 mg … and 150 mg). Olaparib is indicated for the treatment of certain types … for Ahmedabad SEZ-II facility Olaparib tablets recorded annual sales of …

… centralized drug procurement round has selected 55 medicines, including antivirals and diabetes treatments … drug oseltamivir, a first-line diabetes medication called metformin and targeted cancer drug olaparib …

… the UI Carver College of Medicine and senior author of the … treated with the PARP inhibitor olaparib remain disease free for more … can be targeted for future drug discovery.” Targeting RAD52 to … develop these molecules into testable drugs, they need to be …

… the European Society for Medical Oncology Congress 2025, showed … platinum agents. Perhaps these drugs could induce more responses … PARP inhibitor or olaparib [Lynparza]. In that trial, patients who … free of progression off treatment after the transplant. That …

… example, the clinical trial data that supported … , Inc).17 Olaparib (Lynparza ; AstraZeneca Pharmaceuticals LP) was excluded … medical needs and ensuring the safety and efficacy of those treatments … in confirmatory trials for drug applications granted FDA's …

… in all comers. The trial studied Keytruda (pembrolizumab), … treat ovarian cancer. Lynparza (olaparib), which is being jointly … Food and Drug Administration (FDA) for the treatment of adult … efforts include trials focused on evaluating its medicines in earlier …

… 3 SOLO-1 trial (NCT01844986), which solidified olaparib’s role in … highlighted that maintenance olaparib substantially alters the treatment trajectory for patients … with BRCA-mutated disease. Across trials, olaparib …

… . For BRCA-positive patients, olaparib therapy is typically completed first … 6 inhibitor addition once medication access is secured. Treatment sequencing also incorporates … progression, utilizing available clinical trial data to guide decision-making …

… or until disease progression. The trial’s primary end point was … not received subsequent treatment. In total, 42.1% of olaparib patients vs … that both SOLO trials provided consistent evidence supporting olaparib as an effective …